Rocket Pharmaceuticals Inc (NAS:RCKT)
$ 22.975 0.745 (3.35%) Market Cap: 2.09 Bil Enterprise Value: 1.71 Bil PE Ratio: 0 PB Ratio: 4.72 GF Score: 43/100

Rocket Pharmaceuticals Inc to Acquire Renovacor, Extending Leadership in AAV-Based Cardiac Gene Therapy Call Transcript

Sep 20, 2022 / 12:00PM GMT
Release Date Price: $13.69 (-2.00%)
Operator

Good day, and thank you for standing by. Welcome to the Rocket Pharmaceuticals Business Update Call. (Operator Instructions) Please be advised that today's conference is being recorded.

I would now like to hand the conference over to your speaker today, Jessie Yeung, Vice President of IR and Corporate Finance. Please go ahead.

Jessie Yeung
Rocket Pharmaceuticals, Inc. - VP of IR & Corporate Finance

Thank you, operator, and good morning, everyone. Thanks for joining our call today to discuss the combination of Rocket Pharma and Renovacor. This is Jessie Yeung, Vice President of Investor Relations and Corporate Finance, at Rocket Pharmaceuticals. With me on the line today is Dr. Gaurav Shah, CEO of Rocket Pharmaceuticals; and Martin Wilson, Rocket's General Counsel and Chief Compliance Officer.

Before we begin, I would like to briefly discuss the use of forward-looking statements on this conference call. Statements we make on this call may include forward-looking statements, and these forward-looking statements are subject to loan and

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot